{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:31:52Z","timestamp":1792773112021,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05209-x","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:59:02Z","timestamp":1779173942000},"page":"4857-4868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of non-steroidal mineralocorticoid receptor antagonist and SGLT2 inhibitor combination therapy versus SGLT2-inhibitor monotherapy in patients with chronic kidney disease with albuminuria: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0677-5507","authenticated-orcid":false,"given":"Khubaib Mohammad","family":"Murtafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadiya Sajad","family":"Khanday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Vondivillu Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Wajid","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasindu Avishka","family":"Arumapperuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Anilkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Rahim","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merruna Liqua","family":"Chishti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhaib","family":"Andrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"4S","key":"5209_CR1","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4S):S117\u2013S314","journal-title":"Kidney Int"},{"key":"5209_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736","author":"R Agarwal","year":"2020","unstructured":"Agarwal R, Kolkhof P, Bakris G et al (2020) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa736. (in press)","journal-title":"Eur Heart J"},{"issue":"2","key":"5209_CR3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","volume":"67","author":"G Savarese","year":"2024","unstructured":"Savarese G, Lindberg F, Filippatos G, Butler J, Anker SD (2024) Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists. Diabetologia 67(2):246\u2013262. https:\/\/doi.org\/10.1007\/s00125-023-06031-1","journal-title":"Diabetologia"},{"key":"5209_CR4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"5209_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"5209_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"5209_CR7","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL et al (2020) Effect of finerenone on CKD outcomes in type 2 diabetes. N Engl J Med 383:2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"5209_CR8","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing P et al (2022) Finerenone in CKD and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: FIDELITY analysis. Diabetes Care 45:2991\u20132998. https:\/\/doi.org\/10.2337\/dc22-0294","journal-title":"Diabetes Care"},{"key":"5209_CR9","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/ejhf.3294","volume":"26","author":"CSP Lam","year":"2024","unstructured":"Lam CSP et al (2024) Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial. Eur J Heart Fail 26:1727\u20131735. https:\/\/doi.org\/10.1002\/ejhf.3294","journal-title":"Eur J Heart Fail"},{"key":"5209_CR10","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(25)02014-8","volume":"406","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Adlbrecht C et al (2025) Balcinrenone in combination with dapagliflozin in CKD: a randomised, active-controlled phase 2b trial. Lancet 406:2449\u20132460","journal-title":"Lancet"},{"key":"5209_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal R et al (2025) Finerenone with Empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med 393:533\u2013543. https:\/\/doi.org\/10.1056\/NEJMoa2410659","journal-title":"N Engl J Med"},{"issue":"2","key":"5209_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000541686","volume":"56","author":"JP Ferreira","year":"2025","unstructured":"Ferreira JP et al (2025) Mineralocorticoid receptor antagonist combined with SGLT2 inhibitor versus SGLT2 inhibitor alone in CKD: a meta-analysis of randomized trials. Am J Nephrol 56(2):236\u2013242. https:\/\/doi.org\/10.1159\/000541686","journal-title":"Am J Nephrol"},{"key":"5209_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110161","volume":"194","author":"S Tsukamoto","year":"2022","unstructured":"Tsukamoto S et al (2022) Cardiovascular and kidney outcomes of combination therapy with SGLT2 inhibitors and MRAs in T2D and CKD: network meta-analysis. Diabetes Res Clin Pract 194:110161. https:\/\/doi.org\/10.1016\/j.diabres.2022.110161","journal-title":"Diabetes Res Clin Pract"},{"key":"5209_CR14","unstructured":"Higgins JPT, et al. Cochrane handbook for systematic reviews of interventions version 6.5. Cochrane; 2024."},{"key":"5209_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"5209_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M et al (2016) Rayyan: a web and mobile app for systematic reviews. Syst Rev 5:210","journal-title":"Syst Rev"},{"key":"5209_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"5209_CR18","unstructured":"McGuinness LA, Higgins JPT. robvis: visualization tool for risk of bias assessment. Res Synth Methods. 2020;1\u20137."},{"key":"5209_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2288-8-32","volume":"8","author":"JO Friedrich","year":"2008","unstructured":"Friedrich JO et al (2008) Ratio of means method as alternative for continuous outcomes in meta-analysis: simulation study. BMC Med Res Methodol 8:32","journal-title":"BMC Med Res Methodol"},{"key":"5209_CR20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s13300-025-01726-7","volume":"16","author":"EB Stougaard","year":"2025","unstructured":"Stougaard EB et al (2025) Combining SGLT2is, GLP-1 RAs and nsMRAs in diabetes: a scoping review. Diabetes Ther 16:799\u2013811","journal-title":"Diabetes Ther"},{"key":"5209_CR21","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","volume":"33","author":"M Provenzano","year":"2022","unstructured":"Provenzano M et al (2022) Albuminuria-lowering effect of dapagliflozin, eplerenone and their combination in CKD: ROTATE-3 trial. J Am Soc Nephrol 33:1569\u20131580","journal-title":"J Am Soc Nephrol"},{"key":"5209_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle KR et al (2024) Aldosterone synthase inhibition with and without empagliflozin for CKD: randomised controlled trial. Lancet 403:379\u2013390","journal-title":"Lancet"},{"issue":"15","key":"5209_CR23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98720","volume":"3","author":"P Cassis","year":"2018","unstructured":"Cassis P, Locatelli M, Cerullo D et al (2018) SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight 3(15):e98720. https:\/\/doi.org\/10.1172\/jci.insight.98720. (Published 2018 Aug 9)","journal-title":"JCI Insight"},{"key":"5209_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J et al (2018) Selective MR cofactor modulation as basis for finerenone\u2019s antifibrotic activity. Hypertension 71:599\u2013608","journal-title":"Hypertension"},{"key":"5209_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P et al (2014) Finerenone protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64:69\u201378","journal-title":"J Cardiovasc Pharmacol"},{"key":"5209_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P et al (2017) Steroidal and non-steroidal MRAs in HF and cardiorenal diseases. Handb Exp Pharmacol 243:271\u2013305","journal-title":"Handb Exp Pharmacol"},{"issue":"8","key":"5209_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","volume":"24","author":"LCY Liu","year":"2015","unstructured":"Liu LCY et al (2015) Finerenone: third-generation MRA for HF and DKD. Expert Opin Investig Drugs 24(8):1123\u20131135","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl 1","key":"5209_CR28","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.2337\/dc23-S011","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA et al (2023) Chronic kidney disease and risk management: standards of care in diabetes 2023. Diabetes Care 46(Suppl 1):S191-202","journal-title":"Diabetes Care"},{"key":"5209_CR29","doi-asserted-by":"publisher","first-page":"sfad249","DOI":"10.1093\/ckj\/sfad249","volume":"17","author":"FH M\u00e5rup","year":"2023","unstructured":"M\u00e5rup FH et al (2023) Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: open-label randomized trial. Clin Kidney J 17:sfad249","journal-title":"Clin Kidney J"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05209-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05209-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05209-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:17:15Z","timestamp":1792765035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05209-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["5209"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05209-x","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a systematic review and meta-analysis of previously published randomized controlled trials and did not involve any new studies with human participants or animals performed by any of the authors. Therefore, ethical approval and written informed consent were not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}